JD Health International Inc. (86618) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of JD Health International Inc. ¥21.90, price ¥29.62, upside -26.1%, quality 74 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch JD Health International Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 28, 2026.
How to read this chart
39‑month range ¥18.30 – ¥63.75 · fair‑value band ¥13.50 – ¥33.88 · the ¥29.62 price screens above the ¥21.90 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 28, 2026.
Follow JD Health International in your weekly email
Every Wednesday you see whether JD Health International is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People's Republic of China.
Show more
JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People's Republic of China. It provides online medical consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services, as well as internet healthcare, health management, intelligent healthcare, advertising, and technical services. The company also offers home care services, including wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical insurance payment services; and smart healthcare and digital health solutions. In addition, it provides online marketing services to advertisers; and online shopping and hospital services. Further, the company offers smart monitoring and respiratory therapy devices; senior-oriented medical devices; home medical device set-up and support services, including blood glucose meters and oxygen generators; and rapid testing products. Additionally, it provides traditional Chinese medicine (TCM) wellness and professional orthopedic services, as well as operates offline examination and polyclinic centers that offers convenient and professional healthcare services. The company offers pharmaceutical and healthcare products through direct sales, and online marketplace and on-demand retail businesses. It serves pharmaceutical and healthcare product companies. JD Health International Inc. was founded in 2014 and is headquartered in Beijing, the People's Republic of China. JD Health International Inc. is a subsidiary of JD Jiankang Limited.
Stock analysis
JD Health International Inc. (86618) currently trades at ¥29.62, while our model-based Fair Value estimate is ¥21.90, 26.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥25.66 per share, and 4 of the 24 models we run sit above the ¥29.62 price.
Bear case: the Asset-Based group reads lowest at ¥5.71, and 20 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥13.50 (bear) to ¥33.88 (bull), the price of ¥29.62 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 74/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
JD Health International Inc. reported revenue of 73.4B CNY in FY2025 versus 46.7B CNY in FY2022, a compound +16.3%/yr. Reported net income was 5.4B CNY in FY2025, compounding +141.8%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap 182B CNY (≈ $27.2B) · P/S ratio 2.30 · Net margin 7.3% · Return on equity 10.4% · Return on assets 3.7% · Operating margin 7.8% · Revenue (TTM) 79.0B CNY · Revenue growth (YoY) +15.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −26%, 86618 screens richer than that median.
Fair Value models
Bear ¥13.50Fair Value ¥21.90Bull ¥33.88
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+26.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +61.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+61.8%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 6%
⚠ Approximate: the rate leans on 2025, which sits 149% above its own trend.
Compare JD Health International Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 56 stocks
Beats the industry median on 10/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score74 · Top 25%
Fair Value upside+118.9% · Top 25%
Profitability
Return on equity (TTM)10.4% · Above median
Return on assets3.7% · Above median
Net margin (TTM)7.9% · Top 25%
Operating margin (TTM)7.8% · Top 25%
Growth and dividend
Revenue growth15.9% · Top 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "JD Health International Inc. Fair Value". https://www.fairvalue-calculator.com/stock/86618
Frequently asked questions
Is JD Health International Inc. (86618) overvalued or undervalued?
As of Sep 28, 2026, our model estimates a fair value of ¥21.90 versus a price of ¥29.62, about −26% upside (overvalued).
What is the fair value of 86618?
Our model-based fair value for JD Health International Inc. is ¥21.90 (as of Sep 28, 2026), built from audited fundamentals. The current price: ¥29.62.
What is the quality score of 86618?
JD Health International Inc. has a Quality Score of 74/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JD Health International Inc. (86618)?
Our model-based price target is the fair value of ¥21.90 (as of Sep 28, 2026) from 24 valuation models. Cautious scenario ¥13.50, optimistic scenario ¥33.88. It is a calculation from audited fundamentals, not an analyst target.
What is the JD Health International Inc. stock forecast for 2026?
Our models put fair value at ¥21.90, about −26% upside versus a price of ¥29.62 (overvalued). Cautious scenario ¥13.50, optimistic scenario ¥33.88. The calculation is refreshed regularly with new filings.
What is the revenue of JD Health International Inc. (86618)?
JD Health International Inc. reported trailing-twelve-month revenue of about 79.0B CNY (latest available figure, as of Sep 28, 2026).
What is the intrinsic value of JD Health International Inc. (86618)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JD Health International Inc. it is ¥21.90 per share (as of Sep 28, 2026), against a price of ¥29.62. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is JD Health International Inc. stock overvalued or undervalued in 2026?
As of Sep 28, 2026, 86618 trades above its calculated fair value: price ¥29.62, fair value ¥21.90, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 86618?
No. The price is what the market pays today (¥29.62); the fair value is what the company's own numbers justify (¥21.90). For JD Health International Inc. the two are ¥7.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is JD Health International Inc. worth?
The market values JD Health International Inc. at about 182B CNY (market capitalisation, as of Sep 28, 2026). Per share that is ¥29.62; our models calculate a fair value of ¥21.90 per share.
What do the bullish and bearish scenarios say about 86618?
Our models span a range for JD Health International Inc.: cautious scenario ¥13.50, base ¥21.90, optimistic ¥33.88 per share (as of Sep 28, 2026, price ¥29.62). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of JD Health International Inc. (86618)?
Balance-sheet figures for JD Health International Inc. (as of Sep 28, 2026): return on equity 10.4%. They feed the Quality Score of 74/100, which measures business quality independently of the share price.
How far is 86618 from its 52-week high?
JD Health International Inc. trades at ¥29.62, about 53% below its 52-week high of ¥63.40 and 6% above the low of ¥27.86 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of ¥21.90 is for.
Which stocks are comparable to JD Health International Inc.?
From the same area (Healthcare) we also value Alibaba Health Information Technology Limited, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JD Health International Inc. stock attractive at the current price?
The data as of Sep 28, 2026: price ¥29.62, calculated fair value ¥21.90 (−26%), Quality Score 74/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 86618 calculated?
We run JD Health International Inc. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥21.90, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. JD Health International Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JD Health International Inc. (86618)?
The closing price on Oct 2, 2026 was ¥29.62. Our model-based fair value is ¥21.90, about −26% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JD Health International Inc. right now?
A high-quality business (quality 74/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. A fairly wide model range (¥13.50 to ¥33.88) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of JD Health International Inc.
How large is the market capitalisation of JD Health International Inc. (86618)?
The market capitalisation of JD Health International Inc. is 182B CNY (≈ $27.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JD Health International Inc. (86618)?
The price-to-sales ratio of JD Health International Inc. is 2.30 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of JD Health International Inc. (86618)?
The net margin of JD Health International Inc. is 7.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JD Health International Inc. (86618)?
The return on equity (ROE) of JD Health International Inc. is 10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the return on assets of JD Health International Inc. (86618)?
The return on assets (ROA) of JD Health International Inc. is 3.7% (last twelve months). Profit relative to everything the company owns. Harder to inflate than return on equity because debt does not boost it.
What is the operating margin of JD Health International Inc. (86618)?
The operating margin of JD Health International Inc. is 7.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JD Health International Inc. (86618)?
Revenue at JD Health International Inc. is growing +15.9% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at JD Health International Inc. (86618)?
Earnings per share at JD Health International Inc. are growing +32.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch JD Health International Inc. in the live analysis
One click puts JD Health International Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 28, 2026